Iain Ross was appointed to the Board as Non-Executive Chairman in July 2021. He assumed Executive responsibility in January 2023 following the departure of Chief Executive Officer.
Iain Ross is a highly experienced board director with a career in the international life sciences and technology sectors that spans 40 years. He held senior commercial roles at Sandoz, Fisons and Hoffman La Roche before moving into the biotechnology sector where he has been Chairman, CEO and Director of several international biotechnology companies including Kazia Therapeutics Limited, Celltech Group plc, Quadrant Healthcare plc and Redx Pharma plc.
Currently he is Non-Executive Chairman at Silence Therapeutics PLC (NASDAQ); and a non-executive director of BiVictriX Therapeutics plc (LSE). Mr Ross is a qualified Chartered Director, Fellow of the Institute of Directors and Honorary Fellow of Royal Holloway, London University.
Barbara Staehelin was appointed to the Board as Senior Non-Executive Director in July 2021.
Barbara is Non-Executive Chair for Resistell AG. She is a board member at Assura Group, a Swiss medical insurance company where she is President of he Audit and Risk Committee. She is also co-founder and Chair at Axicos AG.
Barbara Staehelin began her professional career in management consultancy, focussing on healthcare at McKinsey and Co., Inc. She has also served as a member of the Global Executive Committee at F. Hoffman-LaRoche Diagnostics. Her wide experience both in senior leadership roles and in founding companies has given her extensive high-level exposure to commercial, regulatory and governance matters in the biotech sector.
Ms. Staehelin holds a Directors Certificate from Harvard University, USA , an MBA from INSEAD Fontainebleau, France and an MSc in biochemistry from ETH Zurich..
Dr Mike Owen was appointed to the Board in December 2015.
He currently serves as a director of Zealand Pharma, Sareum Holdings plc and Ossianix Inc. He is also a member of the scientific advisory board at Avacta Group plc.
Mike’s career in biotech, the pharmaceutical industry and academia spans more than 40 years. He was formerly senior vice president for biopharmaceuticals research at GlaxoSmithKline and was also a founder and chief scientific officer of Kymab Ltd, an antibody based biotech company. He has previously served as a director for BliNK Biomedical SAS. For many years held a research position at the Imperial Cancer Research Fund (now CR-UK) and he has previously served on the scientific advisory board of the CRT Pioneer Fund LP.
He is a Fellow of the Academy of Medical Sciences.
Martin was appointed to the Board in March 2022.
Martin spent 25 years in global investment banking and asset management, culminating as Vice Chair in charge of Wholesale and Commercial Banking for Europe and Asia-Pacific at Toronto Dominion Bank.
Since 2010, Martin has been an active VC / PE investor, portfolio manager, and advisor in life sciences involving a number of Executive and non-Executive positions, completing over 25 transactions (spinouts, financings, M&A, IPOs, divestitures) and has raised over £1bn in investment and co-investment capital.
Martin is co-founder of LSE-listed Arix Bioscience plc (LSE: ARIX) and currently serves as Chairman and CEO of Bradshaw Consulting Ltd. He is CEO of virtual biotech Excalibur Medicines Ltd, Board Director of Interrad Medical and a Board Member of the Liverpool Life Sciences Accelerator Partnership.
In addition to a wealth of experience in the life sciences sector, he also has extensive Governance, Oversight, Audit Committee and Risk Committee experience as well as specific experience in start-up, growth (organic and acquisition), turnaround and consolidation strategies.
John was appointed Chief Financial Officer in September 2022. John joined ReNeuron in October 2014 as Financial Controller and was appointed Company Secretary in June 2021.
John is an experienced finance professional with a breadth of experience gained within a variety of businesses, from large PLCs to family-owned SMEs. He joined ReNeuron, after leaving his role as Finance Director of an insurance business, having previously worked for a number of years in the financial services sector where he specialised in business partnering, helping to drive growth and profitability. During this time, he played a lead role in a number of acquisitions and played a key role in the $1bn sale of a division of Standard Chartered Bank to The Lloyds Banking Group.
John graduated from university with a 1st class honours degree in industrial chemistry and started his career with KPMG, where he qualified as a Chartered Accountant.